Levels of thrombin activatable fibrinolysis inhibitor (TAFI) and protein C inhibitor were also found to be significantly elevated in the bronchoalveolar fluid of patients with interstitial lung disease when compared to healthy controls, which could also add to the hypofibrinolysis observed [31, 32]. The gene discussed is CPB2; the disease is interstitial lung disease.